Targeting specific cancer pathways in prostate cancer without PTEN
Official title: Combined inhibition of ATR and p110β as Therapy in PTEN-deficient Prostate Cancer
Funded at Roswell Park Cancer Institute Corp · NIH-11042240 · Data updated 2026-11-12
This study is exploring a new treatment for prostate cancer that doesn't have the PTEN gene, by combining two specific therapies to see if they can work better together to shrink tumors and help patients feel better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $243,334 |
| NIH project number | 5R21CA288931-02 |
| Project ID | NIH-11042240 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer that is PTEN-deficient.
✕Less likely to help
Patients with prostate cancer that does not involve PTEN mutations or those with early-stage disease may not benefit from this research.
What this research studies
This research investigates a new treatment approach for prostate cancer that lacks the PTEN gene, which is often associated with aggressive disease. The study aims to combine the inhibition of two key proteins, ATR and p110β, to enhance the effectiveness of cancer therapies. By using advanced mouse models that mimic human prostate cancer, researchers will assess how this combination therapy can reduce tumor growth and improve patient outcomes. The goal is to develop a novel strategy that could potentially overcome resistance to existing treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with advanced prostate cancer, particularly those who have not responded to standard treatments.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting the PI3K pathway in cancer treatment, indicating potential for success in this novel combination therapy.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Ding, Liya — Roswell Park Cancer Institute Corp
- Study coordinator: Ding, Liya
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.